O2 - Cabozantinib versus everolimus in patients with advanced renal cell carcinoma from Europe and the rest of the world: subgroup analysis of the METEOR trial

Publication date: November 2018Source: European Urology Supplements, Volume 17, Issue 14Author(s): M. Schmidinger, T. Powles, R.J. Motzer, F. Rolland, G. Gravis, M. Staehler, M. Rink, M. Retz, T. Csoszi, J.A. Mccaffrey, U. De Giorgi, C. Caserta, I. Duran, J.G. Larkin, F. Benzaghou, D. Clary, B. Escudier, T.K. Choueir, N.M. Tannir
Source: European Urology Supplements - Category: Urology & Nephrology Source Type: research